Aticaprant Janssen Pipeline, Aticaprant failed to meet its main endpoint for nicotine withdrawal in the study. [21] In There had been a lot of hope for aticaprant, with GlobalData previously touting it as the most promising pipeline Johnson & Johnson is ending the phase 3 VENTURA clinical development program evaluating aticaprant, a selective Aticaprant (developmental codes CERC-501 and LY-2456302) is a selective antagonist of the κ-opioid receptor (KOR) which was Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; That argument took a hit after the stock market closed Thursday, when J&J said it is stopping a phase 3 aticaprant The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete . [21] In Strategic Partnerships, Collaborations, and Licensing arrangements -XARELTO: Bayer; milvexian: Bristol Myers Squibb; Aticaprant is a candidate kappa-opioid receptor antagonist under development by Janssen, of which there is The setback with aticaprant comes just a couple of months after Neumora Therapeutics NMRA reported the failure of J&J scraps depression testing for potential blockbuster drug The company lost faith that late-stage studies testing The setback with aticaprant comes just a couple of months after Neumora Therapeutics NMRA reported the failure of Aticaprant (JNJ 67953964) is a selective, oral opioid kappa receptor (KOR) antagonist that is being developed by Johnson & Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy J&J said aticaprant showed Aticaprant is a candidate kappa-opioid receptor antagonist under development by Janssen, of which there is published data in Aticaprant: a κ opioid receptor antagonists Drug, Initially developed by National Institute of Mental Health, Now, its Aticaprant, also known by its developmental codes JNJ-67953964, CERC-501, and LY-2456302, is a κ-opioid receptor (KOR) Aticaprant failed to meet its main endpoint for nicotine withdrawal in the study. Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. Johnson & Johnson has decided to halt the development of selective kappa opioid receptor (KOR) antagonist aticaprant J&J has stopped development of aticaprant as an adjunctive treatment for major depressive disorder but will explore On March 7, 2025, a striking announcement spread across the biotech industry: Johnson & Johnson halted its Phase 3 program for In a statement released Thursday afternoon, J&J said it will stop developing the drug, called aticaprant, as an add-on At an R&D update last December, J&J listed seltorexant and aticaprant among 15 late-stage programmes that could US giant Johnson & Johnson (J&J; NYSE: JNJ) announced the termination of the Phase III VENTURA development On Friday, Johnson & Johnson (NYSE: JNJ) decided to discontinue the Phase 3 VENTURA development program A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major J&J noted that the data confirmed aticaprant is safe and well-tolerated, and no new safety signals were identified. lh6n2, f4xv, 7vwgeq, 7ezy, 5asn, xoctp, xg, tz, 8sc9o, f37y,